Terry J. Smith
University of Michigan
219 papers found
Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?
Neuromyelitis optica spectrum disorder
Cerebrospinal fluid biomarkers for predicting development of multiple sclerosis in acute optic neuritis: a population-based prospective cohort study
Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD
HIF2A–LOX Pathway Promotes Fibrotic Tissue Remodeling in Thyroid-Associated Orbitopathy
The insulin-like growth factor-I receptor and its role in thyroid-associated ophthalmopathy
Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy
Is there potential for the approval of monoclonal antibodies to treat thyroid-associated ophthalmopathy?
40 YEARS OF IGF1: IGF1 receptor and thyroid-associated ophthalmopathy
CD34− Orbital Fibroblasts From Patients With Thyroid-Associated Ophthalmopathy Modulate TNF-α Expression in CD34+ Fibroblasts and Fibrocytes
Slit2 Modulates the Inflammatory Phenotype of Orbit-Infiltrating Fibrocytes in Graves’ Disease
Magnetic resonance imaging findings at the first episode of acute optic neuritis
New advances in understanding thyroid-associated ophthalmopathy and the potential role for insulin-like growth factor-I receptor
Response to Krieger et al. re: “TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis” (Thyroid 2017;27:746–747)
A population-based prospective study of optic neuritis
Teprotumumab for Thyroid-Associated Ophthalmopathy
TSHR as a therapeutic target in Graves’ disease
Challenges in Orphan Drug Development: Identification of Effective Therapy for Thyroid-Associated Ophthalmopathy
The authors reply
Building the case for insulin-like growth factor receptor-I involvement in thyroid-associated ophthalmopathy
Missing publications? Search for publications with a matching author name.